Construction and characterization of a high-affinity humanized SM5-1 monoclonal antibody

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• SM5-1 is a mouse monoclonal antibody with high specificity for melanoma, hepatocellular carcinoma, and breast cancer.
• Its potential for cancer targeting therapy is limited by immunogenicity.

Purpose of the Study:

• To construct a humanized version of the SM5-1 antibody to minimize immunogenicity for potential clinical applications.
• To evaluate the antigen-binding affinity and specificity of the humanized SM5-1 antibody.

Main Methods:

• Computer-assisted homology modeling was used to build a molecular model of SM5-1.
• Key mouse framework region (FR) residues important for antigen binding were identified.
• A humanized antibody was generated by grafting mouse complementarity-determining regions (CDRs) and specific mouse FR residues onto a human framework.

Main Results:

• The humanized SM5-1 antibody retained only six murine residues outside of the CDRs.
• The humanized antibody demonstrated comparable affinity and specificity to the parental mouse antibody.
• The humanization process successfully reduced potential immunogenicity while preserving therapeutic efficacy.

Conclusions:

• The humanized SM5-1 antibody is a promising candidate for clinical development in targeting melanoma, hepatocellular carcinoma, and breast cancer.
• This humanized antibody offers a potential solution to the immunogenicity issues associated with murine antibodies.
• Further development may lead to improved cancer therapies with reduced adverse effects.